Stanley-Laman Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,500
| Closed | -$274K | – | 288 |
|
|
2025
Q1 | $274K | Hold |
4,500
| – | – | 0.04% | 242 |
|
|
2024
Q4 | $255K | Hold |
4,500
| – | – | 0.04% | 253 |
|
|
2024
Q3 | $233K | Sell |
4,500
-4,510
| -50% | -$212K | 0.03% | 262 |
|
|
2024
Q2 | $374K | Buy |
9,010
+2,670
| +42% | +$119K | 0.05% | 221 |
|
|
2024
Q1 | $344K | Buy |
6,340
+248
| +4% | +$12.6K | 0.05% | 211 |
|
|
2023
Q4 | $313K | Buy |
6,092
+312
| +5% | +$16.4K | 0.05% | 203 |
|
|
2023
Q3 | $335K | Sell |
5,780
-1,000
| -15% | -$61.3K | 0.06% | 194 |
|
|
2023
Q2 | $434K | Buy |
6,780
+1,007
| +17% | +$67.5K | 0.07% | 179 |
|
|
2023
Q1 | $400K | Buy |
+5,773
| New | +$407K | 0.07% | 182 |
|
|
2022
Q3 | – | Sell |
-5,318
| Closed | -$409K | – | 236 |
|
|
2022
Q2 | $409K | Buy |
+5,318
| New | +$405K | 0.07% | 199 |
|
|
2021
Q2 | – | Sell |
-25,069
| Closed | -$1.58M | – | 248 |
|
|
2021
Q1 | $1.58M | Sell |
25,069
-3,669
| -13% | -$228K | 0.26% | 131 |
|
|
2020
Q4 | $1.78M | Buy |
28,738
+4,339
| +18% | +$267K | 0.32% | 93 |
|
|
2020
Q3 | $1.47M | Sell |
24,399
-862
| -3% | -$51.9K | 0.32% | 87 |
|
|
2020
Q2 | $1.49M | Buy |
25,261
+1,704
| +7% | +$102K | 0.36% | 72 |
|
|
2020
Q1 | $1.31M | Sell |
23,557
-892
| -4% | -$54.5K | 0.4% | 67 |
|
|
2019
Q4 | $1.57M | Buy |
24,449
+18,008
| +280% | +$1.03M | 0.37% | 76 |
|
|
2019
Q3 | $327K | Hold |
6,441
| – | – | 0.08% | 216 |
|
|
2019
Q2 | $292K | Sell |
6,441
-5,587
| -46% | -$260K | 0.07% | 226 |
|
|
2019
Q1 | $574K | Buy |
+12,028
| New | +$599K | 0.14% | 205 |
|
|
2017
Q1 | – | Sell |
-13,800
| Closed | -$806K | – | 235 |
|
|
2016
Q4 | $806K | Hold |
13,800
| – | – | 0.25% | 127 |
|
|
2016
Q3 | $744K | Buy |
13,800
+500
| +4% | +$32.1K | 0.3% | 117 |
|
|
2016
Q2 | $978K | Hold |
13,300
| – | – | 0.38% | 92 |
|
|
2016
Q1 | $850K | Sell |
13,300
-350
| -3% | -$22.1K | 0.16% | 130 |
|
|
2015
Q4 | $939K | Hold |
13,650
| – | – | 0.16% | 150 |
|
|
2015
Q3 | $808K | Hold |
13,650
| – | – | 0.16% | 142 |
|
|
2015
Q2 | $908K | Hold |
13,650
| – | – | 0.17% | 151 |
|
|
2015
Q1 | $880K | Sell |
13,650
-386
| -3% | -$24.2K | 0.16% | 151 |
|
|
2014
Q4 | $829K | Buy |
14,036
+386
| +3% | +$21.8K | 0.16% | 147 |
|
|
2014
Q3 | $699K | Buy |
13,650
+350
| +3% | +$17.5K | 0.14% | 155 |
|
|
2014
Q2 | $645K | Hold |
13,300
| – | – | 0.12% | 163 |
|
|
2014
Q1 | $691K | Buy |
+13,300
| New | +$708K | 0.12% | 170 |
|
Other funds holding BMY
Stanley-Laman Group's BMY Position: Q2 2025 in Review
Stanley-Laman Group sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 4,500 shares — an estimated $274K sold.
Stanley-Laman Group first reported a position in BMY in Q1 2014 and held it in 31 quarters. The position peaked at $1.78M in Q4 2020. 2,297 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Stanley-Laman Group reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
- Stanley-Laman Group sold 4,500 Bristol-Myers Squibb shares in Q2 2025, an estimated $274K.
- Stanley-Laman Group first reported a position in Bristol-Myers Squibb in Q1 2014 and held it in 31 quarters.
- Stanley-Laman Group's Bristol-Myers Squibb position peaked at $1.78M in Q4 2020.
- 2,297 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Stanley-Laman Group's 13F filing for Q2 2025, filed 29 Jul 2025.